Kairos Pharma (NYSE American: KAPA) Highlights Preclinical Data on KROS101 at AACR-JCA Joint Conference

On February 6, 2025, Kairos Pharma, Ltd., a Delaware corporation, released a press announcement regarding its participation in the joint American Association for Cancer Research (AACR) and Japanese Cancer Association (JCA) conference. The company presented preclinical data on its investigational compound, KROS101, a glutocorticoid-induced tumor necrosis factor receptor agonist, during the plenary session of the AACR-JCA Joint Conference titled From Cancer Discovery Science to Therapeutic Innovation.

The AACR-JCA Joint Conference took place from February 1 to February 5, 2025, at the Hyatt Regency Maui in Maui, Hawaii. This event, renowned for uniting prominent researchers from the United States, Japan, and globally, aimed to share the latest advancements in basic, translational, and clinical cancer research. Dr. John S. Yu, the Chief Executive Officer of Kairos Pharma, and Dr. Ramachandran Murali, the Vice President of Research and Development, participated in the conference and introduced the preclinical data on KROS101.

The data showcased during the presentation highlighted KROS101’s potential therapeutic benefits for melanoma and glioblastoma. The talk covered recent findings from in vivo studies demonstrating that KROS101, a potent GITR ligand agonist, aids in enhancing T cell infiltration, proliferation, and the ability to eliminate cancer cells in mouse models of melanoma and human glioblastoma in vitro. It also effectively reduced T reg-mediated suppression, showing promising activity in enabling T cell proliferation and cancer cell killing in melanoma tumors in vivo and glioblastoma tumors in vitro.

KROS101 targets GITRL, a crucial checkpoint cytokine from the tumor necrosis factor ligand family, to regulate T cell function in autoimmune and cancer scenarios. The compound aims to stabilize the active form of GITRL, reducing suppressive T-cells and enhancing cytotoxic T cells. In a preclinical study, KROS101 exhibited notable efficacy in reducing melanoma tumors in a human GITR knock-in mouse model compared to other treatments.

Both Dr. Murali and Dr. Yu expressed optimism regarding the potential of KROS101 in expanding T cell responses and offering innovative cancer therapies based on the presented preclinical data.

Please note that the information contained in Exhibit 99.1 and presented in this report is provided as furnished material and shall not be deemed filed under the Securities Exchange Act of 1934. Additionally, this report will not be considered an admission to the materiality of the information included. This release includes forward-looking statements; readers are advised to consider various factors that may affect the accuracy of such statements while evaluating the company’s future performance.

For further details about Kairos Pharma and its ongoing initiatives, please refer to the company’s official website.

Contact:
CORE IR
Louie Toma
[email protected]

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Kairos Pharma’s 8K filing here.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.